Yanhong Zhou
Research Subjects
Yanhong Zhou has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Ying Yuan
The University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications - J. Jack. Lee
Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX
3 shared publications - Ruitao Lin
Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA
2 shared publications Aarti R. Chawla
Eli Lilly and Company, Indianapolis, IN
1 shared publication- Bastien Nguyen
Eli Lilly and Company, Indianapolis, IN
1 shared publication Cynthia Sandoval
Eli Lilly and Company, Indianapolis, IN
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 20 March 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (9) , 1101-1112
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein, we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. METHODS: This double-blind, randomized phase III study enrolled patients with disease progression on previous CDK4/6i plus aromatase inhibitor as initial therapy for advanced disease or recurrence on/after adjuvant CDK4/6i + ET. Patients were randomly assigned (1:1) to abemaciclib + fulvestrant or placebo + fulvestrant. The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included PFS by blinded independent central review, objective response rate (ORR), and safety. RESULTS: This study randomly assigned 368 patients (abemaciclib + fulvestrant, n = 182 placebo + fulvestrant, n = 186). At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001). A consistent treatment effect was seen across major clinical and genomic subgroups, including with/without ESR1 or PIK3CA mutations. Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015). No new safety signals were observed, with findings consistent with the known safety profile of abemaciclib. CONCLUSION: Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2– ABC, offering an additional targeted therapy option for these patients.
- 20 March 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (9) , 1101-1112
Top Cited PapersOpen AccessAbemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein, we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. METHODS: This double-blind, randomized phase III study enrolled patients with disease progression on previous CDK4/6i plus aromatase inhibitor as initial therapy for advanced disease or recurrence on/after adjuvant CDK4/6i + ET. Patients were randomly assigned (1:1) to abemaciclib + fulvestrant or placebo + fulvestrant. The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included PFS by blinded independent central review, objective response rate (ORR), and safety. RESULTS: This study randomly assigned 368 patients (abemaciclib + fulvestrant, n = 182 placebo + fulvestrant, n = 186). At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001). A consistent treatment effect was seen across major clinical and genomic subgroups, including with/without ESR1 or PIK3CA mutations. Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015). No new safety signals were observed, with findings consistent with the known safety profile of abemaciclib. CONCLUSION: Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2– ABC, offering an additional targeted therapy option for these patients.
- 5 November 2022
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (2) , 300-311
AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials
Designing Phase I clinical trials is challenging when accrual is slow or sample size is limited. The corresponding key question is: how to efficiently and reliably identify the maximum tolerated dose (MTD) using a sample size as small as possible? We propose model‐assisted and model‐based designs with adaptive intrapatient dose escalation (AIDE) to address this challenge. AIDE is adaptive in that the decision of conducting intrapatient dose escalation depends on both the patient's individual safety data, as well as other enrolled patient's safety data. When both data indicate reasonable safety, a patient may perform intrapatient dose escalation, generating toxicity data at more than one dose. This strategy not only provides patients the opportunity to receive higher potentially more effective doses, but also enables efficient statistical learning of the dose‐toxicity profile of the treatment, which dramatically reduces the required sample size. Simulation studies show that the proposed designs are safe, robust, and efficient to identify the MTD with a sample size that is substantially smaller than conventional interpatient dose escalation designs. Practical considerations are provided and R code for implementing AIDE is available upon request.
- 5 November 2022
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (2) , 300-311
AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials
Designing Phase I clinical trials is challenging when accrual is slow or sample size is limited. The corresponding key question is: how to efficiently and reliably identify the maximum tolerated dose (MTD) using a sample size as small as possible? We propose model‐assisted and model‐based designs with adaptive intrapatient dose escalation (AIDE) to address this challenge. AIDE is adaptive in that the decision of conducting intrapatient dose escalation depends on both the patient's individual safety data, as well as other enrolled patient's safety data. When both data indicate reasonable safety, a patient may perform intrapatient dose escalation, generating toxicity data at more than one dose. This strategy not only provides patients the opportunity to receive higher potentially more effective doses, but also enables efficient statistical learning of the dose‐toxicity profile of the treatment, which dramatically reduces the required sample size. Simulation studies show that the proposed designs are safe, robust, and efficient to identify the MTD with a sample size that is substantially smaller than conventional interpatient dose escalation designs. Practical considerations are provided and R code for implementing AIDE is available upon request.
- 19 May 2021
- Published by Wiley in Pharmaceutical Statistics
- Vol. 20 (6) , 1183-1199
The use of local and nonlocal priors in Bayesian test‐based monitoring for single‐arm phase II clinical trials
Bayesian sequential monitoring is widely used in adaptive phase II studies where the objective is to examine whether an experimental drug is efficacious. Common approaches for Bayesian sequential monitoring are based on posterior or predictive probabilities and Bayesian hypothesis testing procedures using Bayes factors. In the first part of the paper, we briefly show the connections between test‐based (TB) and posterior probability‐based (PB) sequential monitoring approaches. Next, we extensively investigate the choice of local and nonlocal priors for the TB monitoring procedure. We describe the pros and cons of different priors in terms of operating characteristics. We also develop a user‐friendly Shiny application to implement the TB design.
- 19 May 2021
- Published by Wiley in Pharmaceutical Statistics
- Vol. 20 (6) , 1183-1199
The use of local and nonlocal priors in Bayesian test‐based monitoring for single‐arm phase II clinical trials
Bayesian sequential monitoring is widely used in adaptive phase II studies where the objective is to examine whether an experimental drug is efficacious. Common approaches for Bayesian sequential monitoring are based on posterior or predictive probabilities and Bayesian hypothesis testing procedures using Bayes factors. In the first part of the paper, we briefly show the connections between test‐based (TB) and posterior probability‐based (PB) sequential monitoring approaches. Next, we extensively investigate the choice of local and nonlocal priors for the TB monitoring procedure. We describe the pros and cons of different priors in terms of operating characteristics. We also develop a user‐friendly Shiny application to implement the TB design.
- Open Access
- 4 December 2020
- Published by Springer Nature in Research Square
IPDfromKM: Reconstruct Individual Patient Data from Published Kaplan-Meier Survival Curves
BackgroundWhen applying secondary analysis on published survival data, it is critical to obtain each patient’s raw data, because the individual patient data (IPD) approach has been considered as the gold standard of data analysis. However, researchers often lack access to the IPD. We aim to propose a straightforward and robust approach to help researchers to obtain IPD from published survival curves with a friendly software platform. ResultsImproving upon the existing methods, we proposed an easy-to-use, two-stage approach to reconstruct IPD from published Kaplan-Meier (K-M) curves. Stage 1 extracts raw data coordinates and Stage 2 reconstructs IPD using the proposed method. To facilitate the use of the proposed method, we develop the R package IPDfromKM and an accompanied web-based Shiny application. Both the R package and Shiny application can be used to extract raw data coordinates from published K-M curves, reconstruct IPD from data coordinates extracted, visualize the reconstructed IPD, assess the accuracy of the reconstruction, and perform secondary analysis on the IPD. We illustrate the use of the R package and the Shiny application with K-M curves from published studies. Extensive simulations and real world data applications demonstrate that the proposed method has high accuracy and great reliability in estimating the number of events, number of patients at risk, survival probabilities, median survival times, as well as hazard ratios. ConclusionsIPDfromKM has great flexibility and accuracy to reconstruct IPD from published K-M curves with different shapes. We believe that the R package and the Shiny application will greatly facilitate the potential use of quality IPD data and advance the use of secondary data to make informed decision in medical research.
- 4 December 2020
- Published by Springer Nature in Research Square
Open AccessIPDfromKM: Reconstruct Individual Patient Data from Published Kaplan-Meier Survival Curves
BackgroundWhen applying secondary analysis on published survival data, it is critical to obtain each patient’s raw data, because the individual patient data (IPD) approach has been considered as the gold standard of data analysis. However, researchers often lack access to the IPD. We aim to propose a straightforward and robust approach to help researchers to obtain IPD from published survival curves with a friendly software platform. ResultsImproving upon the existing methods, we proposed an easy-to-use, two-stage approach to reconstruct IPD from published Kaplan-Meier (K-M) curves. Stage 1 extracts raw data coordinates and Stage 2 reconstructs IPD using the proposed method. To facilitate the use of the proposed method, we develop the R package IPDfromKM and an accompanied web-based Shiny application. Both the R package and Shiny application can be used to extract raw data coordinates from published K-M curves, reconstruct IPD from data coordinates extracted, visualize the reconstructed IPD, assess the accuracy of the reconstruction, and perform secondary analysis on the IPD. We illustrate the use of the R package and the Shiny application with K-M curves from published studies. Extensive simulations and real world data applications demonstrate that the proposed method has high accuracy and great reliability in estimating the number of events, number of patients at risk, survival probabilities, median survival times, as well as hazard ratios. ConclusionsIPDfromKM has great flexibility and accuracy to reconstruct IPD from published K-M curves with different shapes. We believe that the R package and the Shiny application will greatly facilitate the potential use of quality IPD data and advance the use of secondary data to make informed decision in medical research.
- 1 November 2020
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 4 (4) , 1393-1402
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies
PURPOSE: For immunotherapy, such as checkpoint inhibitors and chimeric antigen receptor T-cell therapy, where the efficacy does not necessarily increase with the dose, the maximum tolerated dose may not be the optimal dose for treating patients. For these novel therapies, the objective of dose-finding trials is to identify the optimal biologic dose (OBD) that optimizes patients’ risk-benefit trade-off. METHODS: We propose a simple and flexible Bayesian optimal interval phase I/II (BOIN12) trial design to find the OBD that optimizes the risk-benefit trade-off. The BOIN12 design makes the decision of dose escalation and de-escalation by simultaneously taking account of efficacy and toxicity and adaptively allocates patients to the dose that optimizes the toxicity-efficacy trade-off. We performed simulation studies to evaluate the performance of the BOIN12 design. RESULTS: Compared with existing phase I/II dose-finding designs, the BOIN12 design is simpler to implement, has higher accuracy to identify the OBD, and allocates more patients to the OBD. One of the most appealing features of the BOIN12 design is that its adaptation rule can be pretabulated and included in the protocol. During the trial conduct, clinicians can simply look up the decision table to allocate patients to a dose without complicated computation. CONCLUSION: The BOIN12 design is simple to implement and yields desirable operating characteristics. It overcomes the computational and implementation complexity that plagues existing Bayesian phase I/II dose-finding designs and provides a useful design to optimize the dose of immunotherapy and targeted therapy. User-friendly software is freely available to facilitate the application of the BOIN12 design.
- 1 November 2020
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 4 (4) , 1393-1402
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies
PURPOSE: For immunotherapy, such as checkpoint inhibitors and chimeric antigen receptor T-cell therapy, where the efficacy does not necessarily increase with the dose, the maximum tolerated dose may not be the optimal dose for treating patients. For these novel therapies, the objective of dose-finding trials is to identify the optimal biologic dose (OBD) that optimizes patients’ risk-benefit trade-off. METHODS: We propose a simple and flexible Bayesian optimal interval phase I/II (BOIN12) trial design to find the OBD that optimizes the risk-benefit trade-off. The BOIN12 design makes the decision of dose escalation and de-escalation by simultaneously taking account of efficacy and toxicity and adaptively allocates patients to the dose that optimizes the toxicity-efficacy trade-off. We performed simulation studies to evaluate the performance of the BOIN12 design. RESULTS: Compared with existing phase I/II dose-finding designs, the BOIN12 design is simpler to implement, has higher accuracy to identify the OBD, and allocates more patients to the OBD. One of the most appealing features of the BOIN12 design is that its adaptation rule can be pretabulated and included in the protocol. During the trial conduct, clinicians can simply look up the decision table to allocate patients to a dose without complicated computation. CONCLUSION: The BOIN12 design is simple to implement and yields desirable operating characteristics. It overcomes the computational and implementation complexity that plagues existing Bayesian phase I/II dose-finding designs and provides a useful design to optimize the dose of immunotherapy and targeted therapy. User-friendly software is freely available to facilitate the application of the BOIN12 design.
- 1 May 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 92, 105972
Keyboard design for phase I drug-combination trials
- 1 May 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 92, 105972
Keyboard design for phase I drug-combination trials
- 17 October 2019
- Published by Wiley in Statistics in Medicine
- Vol. 38 (28) , S5299-S5316
A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
In the era of targeted therapy and immunotherapy, the objective of dose finding is often to identify the optimal biological dose (OBD), rather than the maximum tolerated dose. We develop a utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to find the OBD. We jointly model toxicity and efficacy using a multinomial‐Dirichlet model, and employ a utility function to measure dose risk‐benefit trade‐off. The U‐BOIN design consists of two seamless stages. In stage I, the Bayesian optimal interval design is used to quickly explore the dose space and collect preliminary toxicity and efficacy data. In stage II, we continuously update the posterior estimate of the utility for each dose after each cohort, using accumulating efficacy and toxicity from both stages I and II, and then use the posterior estimate to direct the dose assignment and selection. Compared to existing phase I/II designs, one prominent advantage of the U‐BOIN design is its simplicity for implementation. Once the trial is designed, it can be easily applied using predetermined decision tables, without complex model fitting and estimation. Our simulation study shows that, despite its simplicity, the U‐BOIN design is robust and has high accuracy to identify the OBD. We extend the design to accommodate delayed efficacy by leveraging the short‐term endpoint (eg, immune activity or other biological activity of targeted agents), and using it to predict the delayed efficacy outcome to facilitate real‐time decision making. A user‐friendly software to implement the U‐BOIN is freely available at www.trialdesign.org.
- 17 October 2019
- Published by Wiley in Statistics in Medicine
- Vol. 38 (28) , S5299-S5316
A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
In the era of targeted therapy and immunotherapy, the objective of dose finding is often to identify the optimal biological dose (OBD), rather than the maximum tolerated dose. We develop a utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to find the OBD. We jointly model toxicity and efficacy using a multinomial‐Dirichlet model, and employ a utility function to measure dose risk‐benefit trade‐off. The U‐BOIN design consists of two seamless stages. In stage I, the Bayesian optimal interval design is used to quickly explore the dose space and collect preliminary toxicity and efficacy data. In stage II, we continuously update the posterior estimate of the utility for each dose after each cohort, using accumulating efficacy and toxicity from both stages I and II, and then use the posterior estimate to direct the dose assignment and selection. Compared to existing phase I/II designs, one prominent advantage of the U‐BOIN design is its simplicity for implementation. Once the trial is designed, it can be easily applied using predetermined decision tables, without complex model fitting and estimation. Our simulation study shows that, despite its simplicity, the U‐BOIN design is robust and has high accuracy to identify the OBD. We extend the design to accommodate delayed efficacy by leveraging the short‐term endpoint (eg, immune activity or other biological activity of targeted agents), and using it to predict the delayed efficacy outcome to facilitate real‐time decision making. A user‐friendly software to implement the U‐BOIN is freely available at www.trialdesign.org.
- 19 November 2018
- Published by Springer Publishing Company
Early Phase Clinical Trials
The objective of most phase I oncology trials is to find the maximum tolerated dose (MTD), which is defined as the dose with the dose-limiting toxicity (DLT) probability closest to the target DLT rate. Phase I trials are critically important for determining the MTD for further investigation in subsequent phase II or III trials. Numerous phases I trial designs have been proposed to find the MTD. These designs are generally classified into algorithm-based designs, model-based designs, and model-assisted designs. This chapter discuses early phase clinical trials. It begins with a brief discussion on algorithm-based designs, model-based designs, and model-assisted designs. It provides the comparison of phase 1 designs followed by the single-agent trials with molecularly targeted and Immunotherapy agents. The chapter also provides drug-combination trials and combination trails to find one MTD and also combination trails to find multiple MTD. Finally it provides phase II clinical trial design.
- 19 November 2018
- Published by Springer Publishing Company
Early Phase Clinical Trials
The objective of most phase I oncology trials is to find the maximum tolerated dose (MTD), which is defined as the dose with the dose-limiting toxicity (DLT) probability closest to the target DLT rate. Phase I trials are critically important for determining the MTD for further investigation in subsequent phase II or III trials. Numerous phases I trial designs have been proposed to find the MTD. These designs are generally classified into algorithm-based designs, model-based designs, and model-assisted designs. This chapter discuses early phase clinical trials. It begins with a brief discussion on algorithm-based designs, model-based designs, and model-assisted designs. It provides the comparison of phase 1 designs followed by the single-agent trials with molecularly targeted and Immunotherapy agents. The chapter also provides drug-combination trials and combination trails to find one MTD and also combination trails to find multiple MTD. Finally it provides phase II clinical trial design.
- 21 August 2018
- Published by Springer Nature
- p. 205-233
Phase I Cancer Clinical Trial Design: Single and Combination Agents
- 21 August 2018
- Published by Springer Nature
- p. 205-233
Phase I Cancer Clinical Trial Design: Single and Combination Agents